📄 medicine

Triglyceride-Glucose Index Adjusted for Body Mass Index and Risk of MASLD: Evidence from a Cross-Sectional Study

This cross-sectional study of 16,844 U.S. adults demonstrates that the combined Triglyceride-Glucose Index and Weight-Adjusted Waist Index (TyG-WWI) is a superior predictor of metabolic dysfunction-associated steatotic liver disease (MASLD) risk compared to either indicator alone, particularly among individuals with a lower BMI.

Original authors: Jin’e Li, Jiajun Qiu, Tiantian Cui, Shan Xu, Ziwei Zeng, Yuying Zhang, Shiqi Yang, Jianping Liu

Published 2026-06-28

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Jin’e Li, Jiajun Qiu, Tiantian Cui, Shan Xu, Ziwei Zeng, Yuying Zhang, Shiqi Yang, Jianping Liu

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Picture: Finding the "Smoking Gun" for Liver Fat

Imagine your liver is a warehouse. In a healthy person, the warehouse is clean and organized. In people with MASLD (Metabolic dysfunction-associated steatotic liver disease), the warehouse is getting cluttered with extra fat. This isn't just about being overweight; it's about how your body handles sugar and fat.

Doctors have been looking for a simple way to spot this "clutter" early, before it causes serious damage. They have a few tools, but they wanted to know: Is there a better tool that combines two different clues to give a more accurate warning?

The Tools: Two Separate Clues

The researchers looked at two existing "clues" that doctors already use:

The TyG Index (The Sugar-Fat Meter): Think of this as a gauge that measures how well your body is handling sugar and fat in your blood. If your blood sugar and triglycerides (a type of fat) are high, this meter goes up. It tells you, "Hey, your body is struggling to process energy."
The WWI (The Body Shape Meter): This is a bit like measuring how much "weight" is packed around your waist relative to your total body weight. It helps identify if someone carries their fat in a dangerous way (around the middle) rather than just being generally heavy.

The Experiment: Mixing the Clues

The researchers asked: What happens if we combine these two meters into one super-tool?

They created a new calculation called TyG-WWI. Imagine taking the "Sugar-Fat Meter" and the "Body Shape Meter," gluing them together, and creating a single, powerful detector.

To test this, they looked at data from 16,844 American adults (a huge, representative group). They checked who had the "cluttered warehouse" (MASLD) and compared their scores on the three tools: the old Sugar-Fat Meter, the old Body Shape Meter, and the new Super-Tool.

What They Found

The results were clear, like finding a flashlight that sees in the dark better than the others:

The New Tool Won: The combined TyG-WWI was the best at predicting who had the liver fat. It was significantly more accurate than looking at the sugar/fat levels alone or the body shape alone.
The "Dose-Response" Effect: Think of this like turning up the volume on a radio. As the TyG-WWI score got higher, the risk of having the liver fat got dramatically higher. The people with the highest scores were much more likely to have the condition than those with low scores.
The "Hidden" Group: Interestingly, the new tool was especially good at spotting the problem in people who weren't extremely obese (BMI under 30). Often, doctors might miss liver fat in people who look "normal" weight, but this new tool could still see the warning signs.

How They Tested It

The "Scorecard" (ROC Analysis): They used a statistical test to see how often the tools were right. The new TyG-WWI got a score of 0.84, while the old tools got around 0.78 and 0.77. In the world of medical testing, a higher score means the tool is better at telling the difference between a healthy liver and a fatty one.
The "Curve" (RCS Analysis): They checked if the relationship was a straight line or a curve. The new tool showed a unique, curved relationship, suggesting it captures a complex pattern that the simple tools miss.

The Bottom Line

This study suggests that if you want to know if someone is at risk for fatty liver disease, looking at both their blood sugar/fat levels and their body shape distribution together gives you a much clearer picture than looking at either one alone.

The researchers call this new combined score (TyG-WWI) a "robust and superior predictor." It's like upgrading from a single-lens camera to a high-definition lens: it sees the problem more clearly, especially in people who might otherwise slip through the cracks.

Important Note: The study looked at data from a specific point in time (a snapshot), so it can tell us what is associated with the disease, but it doesn't prove that changing the score will cure the disease. However, it offers a very promising, simple way to screen for the problem early.

Technical Summary: Triglyceride-Glucose Index Adjusted for Body Mass Index and Risk of MASLD

Problem Statement
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rapidly growing global health concern, characterized by hepatic steatosis accompanied by at least one cardiometabolic risk factor. While the triglyceride-glucose (TyG) index is a recognized biomarker for insulin resistance and metabolic risk, it fails to account for the influence of obesity on insulin sensitivity. Conversely, traditional obesity metrics like Body Mass Index (BMI) and Waist Circumference (WC) have limitations, including the "obesity paradox." The Weight-Adjusted Waist Index (WWI) has been proposed as a superior measure of adiposity, and the composite TyG-WWI index has shown promise in predicting cardiovascular outcomes. However, the specific predictive value of TyG-WWI for MASLD, and whether it outperforms TyG or WWI individually, remains unexplored.

Methodology
This cross-sectional study utilized data from the National Health and Nutrition Examination Survey (NHANES) spanning 1999–2018.

Study Population: From an initial pool of 101,316 participants, the final analysis included 16,844 U.S. adults after excluding individuals under 18, those with missing MASLD diagnostic data, missing TyG-WWI data, moderate-to-heavy alcohol consumption, or hepatitis infections.
MASLD Definition: MASLD was defined according to Delphi consensus criteria: presence of steatotic liver disease (SLD) via the U.S. Fatty Liver Index (US-FLI ≥ 30) plus at least one cardiometabolic risk factor (overweight/obesity, hyperglycemia, hypertension, hypertriglyceridemia, or low HDL-C), excluding other chronic liver causes.
Exposure Variables:
- TyG Index: Calculated as $\ln(TG \times FBG / 2)$ , where TG is triglycerides and FBG is fasting blood glucose.
- WWI: Calculated as $\sqrt{Weight} / Waist\ Circumference$ .
- TyG-WWI: Defined as the product of the TyG index and WWI ( $TyG \times WWI$ ).
Statistical Analysis: The study employed survey-weighted methods to ensure national representativeness. Associations were evaluated using multivariable logistic regression across three models (unadjusted, adjusted for age/sex, and fully adjusted for demographics, lifestyle, and comorbidities). Diagnostic performance was assessed via Receiver Operating Characteristic (ROC) curves and DeLong's test. Dose-response relationships were explored using Restricted Cubic Spline (RCS) analysis. Subgroup analyses and interaction tests were conducted to examine effect modifications.

Key Results

Baseline Characteristics: Among the 16,844 participants, 5,587 (33.2%) had MASLD. The MASLD group was significantly older, more likely to be male and Non-Hispanic White, and exhibited higher values for TyG, WWI, and TyG-WWI compared to the non-MASLD group.
Association with MASLD Risk:
- In fully adjusted models, each standard deviation (SD) increase in TyG, WWI, and TyG-WWI was associated with significantly higher MASLD risk (Odds Ratios [OR]: 2.93, 2.35, and 4.50, respectively).
- Quartile analysis revealed a clear dose-response relationship. The highest quartile (Q4) of TyG-WWI showed the strongest association with MASLD compared to the lowest quartile (Q1), with an adjusted OR of 11.73 (95% CI: 9.12–15.09).
Diagnostic Performance: ROC analysis demonstrated that TyG-WWI had superior diagnostic accuracy (Area Under the Curve [AUC] = 0.8410) compared to TyG (AUC = 0.7880) and WWI (AUC = 0.7729), with both comparisons being statistically significant ( $p < 0.01$ ). The optimal threshold for TyG-WWI was identified at 96.21.
Dose-Response Relationships: RCS analysis indicated linear associations for TyG and WWI with MASLD risk, whereas TyG-WWI exhibited a nonlinear relationship ( $p = 0.0092$ ).
Subgroup Analysis: The association between TyG-WWI and MASLD was consistent across age, sex, ethnicity, and comorbidity subgroups. Notably, the association was significantly stronger in individuals with a BMI < 30 kg/m² (OR 5.12) compared to those with BMI ≥ 30 kg/m² (OR 3.82), with a significant interaction ( $p$ -interaction = 0.0025).

Significance and Claims
The authors conclude that TyG-WWI is a robust and superior predictor of MASLD risk in U.S. adults, outperforming the TyG index or WWI when used alone. By integrating metabolic indicators (glucose-lipid metabolism) with anthropometric data (fat distribution adjusted for weight), TyG-WWI provides a more comprehensive reflection of insulin resistance and obesity-related risk.

The paper claims that this combined indicator holds potential for:

Early Identification: Facilitating the early detection of MASLD, particularly in clinical settings where liver biopsy is not feasible.
Risk Stratification: Offering a simple, cost-effective tool for risk stratification using routinely collected clinical data (fasting glucose, triglycerides, weight, and waist circumference).
Targeted Screening: Specifically aiding in the identification of high-risk individuals with lower BMI, where traditional obesity metrics might underestimate risk.

The study acknowledges limitations, including its cross-sectional design (precluding causal inference), reliance on ultrasound-based diagnosis rather than biopsy, and the need for validation in non-U.S. populations. However, it positions TyG-WWI as a valuable epidemiological tool for enhancing the understanding and management of MASLD.